Biogen (BIIB) Spikes 14% After FDA Posts Briefing Documents for Alzheimer's Drug Aducanumab
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
FDA Giving Biogen (BIIB) Option for Aducanumab Approval on Efficacy from ENGAGE Trial, Shares Worth $443 on Approval - Truist
November 4, 2020 10:54 AM ESTTruist Securities analyst Robyn Karnauskas weighed in on the FDA briefing documents for Biogen's (NASDAQ: BIIB) aducanumab, saying the FDA is giving BIIB the option for approval based on efficacy data from one trial (ENGAGE).
The analyst commented, "While we continue to review the FDA... More
Biogen (BIIB) Halted on LUDP
November 4, 2020 10:12 AM ESTBiogen (NASDAQ: BIIB) Halted on LUDP
... More